The Effect of the Intra-gastric Balloon on Gastric Emptying and the DeMeester Score

Barrichello, Sérgio A.; Badurdeen, Dilhana; Hedjoudje, Abdellah; Neto, Manoel Galvão; Yance, Robin; Veinert, Andre; Fayad, Lea; Şimşek, Halis; Grecco, Eduardo; Souza, Thiago Ferreira de; Teixeira, C.R.; Nunes, Giovana Barros; Kalloo, Anthony N.; Khashab, Mouen A.; Kumbhari, Vivek

doi:10.1007/s11695-019-04039-4

Cited by 18 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another systemic review demonstrated that GERD is a common complication experienced by patients treated with IGB (14.3%), but the proportion with esophagitis was relatively small (2.8%) [ 18 ]. Another study examined how IGB affects the DeMeester score [ 25 ]. In that study, LESp did not change significantly after IGB treatment, but the DeMeester score increased [ 25 ], suggesting that GERD caused by IGB treatment is not simply a change in LESp but is caused by other mechanisms.…”

Section: Intragastric Balloonmentioning

confidence: 99%

“…Another study examined how IGB affects the DeMeester score [ 25 ]. In that study, LESp did not change significantly after IGB treatment, but the DeMeester score increased [ 25 ], suggesting that GERD caused by IGB treatment is not simply a change in LESp but is caused by other mechanisms. Placing an IGB may cause temporary changes in LESp and the physiology of the stomach, TLESR threshold, and regurgitation [ 26 ].…”

Section: Intragastric Balloonmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Endoscopic Bariatric and Metabolic Therapies on Gastroesophageal Reflux Disease

Kim

2021

Medicina

View full text Add to dashboard Cite

Obesity is a chronic disease that is becoming increasingly more prevalent and is associated with many health problems, such as metabolic syndrome. The treatment options for obese patients include lifestyle modification, medications, endoscopic bariatric and metabolic therapies (EBMTs), and surgery. In particular, EBMTs have an excellent therapeutic effect and are less invasive than bariatric surgery. Although it is clear that EBMTs are relatively safe procedures, they can result in several adverse events. Among them, the relationship between EBMTs and gastroesophageal reflux disease (GERD) is unclear. Several studies have demonstrated that an intragastric balloon (IGB) may worsen GERD. There are a few studies on the effects of endoscopic sleeve gastroplasty (ESG) on GERD, but the linking evidence is insufficient. However, the conclusion is not simple. Because obesity is an important cause of GERD, and GERD naturally improves with weight loss after EBMTs, it is not easy to evaluate accurately the effect of EBMTs on GERD. This review aimed to discuss the effect of EBMTs on GERD and suggest future research directions.

show abstract

Section: Intragastric Balloonmentioning

confidence: 99%

Section: Intragastric Balloonmentioning

confidence: 99%

The Effect of Endoscopic Bariatric and Metabolic Therapies on Gastroesophageal Reflux Disease

Kim

2021

Medicina

View full text Add to dashboard Cite

show abstract

“…1). The fluid balloons decrease gastric emptying of solids which may be an aspiration risk if patients require anesthesia while the balloon is in place [27]. Endoscopic sleeve gastroplasty (Overstitch, Apollo Endosurgery, Austin, TX, USA) and primary obesity surgery endolumenal (POSE, Incisionless Operating Platform, USGI, Medical, San Clemente, CA, USA) are techniques to modify the stomach's shape to create a smaller gastric reservoir.…”

Section: Endoscopic Bariatric and Metabolic Therapy - Gastric Techniquesmentioning

confidence: 99%

Advanced endoscopic gastrointestinal techniques for the bariatric patient: implications for the anesthesia provider

Kim

Spiro²,

Hatzidais³

et al. 2021

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

Purpose of reviewThe incidence of obesity and the use of endoscopy have risen concurrently throughout the 21st century. Bariatric patients may present to the endoscopy suite for primary treatments as well as preoperatively and postoperatively from bariatric surgery. However, over the past 10 years, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as viable alternatives to more invasive surgical approaches for weight loss. Recent findingsThe United States Food and Drug Administration (FDA) has approved several different gastric EBMTs including aspiration therapy, intragastric balloons, and endoscopic suturing. Other small intestine EBMTs including duodenal mucosal resurfacing, endoluminal magnetic partial jejunal diversion, and Duodenal-Jejunal Bypass Liner are not yet FDA approved, but are actively being investigated. SummaryObesity causes anatomic and physiologic changes to every aspect of the human body. All EBMTs have specific nuances with important implications for the anesthesiologist. By considering both patient and procedural factors, the anesthesiologist will be able to perform a safe and effective anesthetic.

show abstract

“…Current guidelines suggest bariatric surgery as the most potent treatment tool for patients with class-3 obesity or those with class-2 obesity compounded by an obesity-related comorbidity [2][3][4]. However, although treating obesity in early stages is advised before the development of comorbidities, bariatric surgery is not a first-line option [2,[4][5][6]. Endoscopic bariatric procedures (EBPs) are more effective than pharmacotherapy and lifestyle changes and offer a lower rate of side effects compared to bariatric surgery [7,8].…”

Section: Introductionmentioning

confidence: 99%

İntragastrik Balon ve Botulinum Toksin Enjeksiyonunun Kilo Kaybı Üzerine Kısa Dönem Etkilerinin Karşılaştırılması

2022

Archives of Clinical and Experimental Medicine

View full text Add to dashboard Cite

Aim: To compare the effects of endoscopic intragastric balloon (IGB) placement and intragastric botulinum toxin-A (BTX-A) injection in terms of weight loss among patients with non-morbid obesity. Methods: This retrospective single center study was conducted between 01.08.2020 and 01.01.2022. A total of 39 patients with a body mass index (BMI) of <40 without comorbidities were included in the study. Nineteen underwent intragastric BTX-A injection and 20 underwent IGB placement. Patients were evaluated 1 month and 6 months after the procedures. Results: Mean age was 39.4 ± 8.6 in the BTX-A group and 37.3 ± 10.4 in the IGB group (p = 0.496). 78.9% of the BTX-A group and 75.0% of the IGB group were female (p = 1.000). In both groups, the median weight 1 month after the procedure was significantly lower than before the procedure, and the median weight 6 months after the procedure was significantly lower than 1 month after the procedure (p<0.001 for both groups). The median weight loss in the IGB group at both the 1st and 6th months was significantly greater than the corresponding values of the BTX-A group (p < 0.001 for both). Conclusion: IGB insertion appears to be a more successful endoscopic bariatric procedure than intragastric BTX-A injection, as measured by weight loss at post-intervention 1 month and 6 months. IGB may be preferred in patients with a BMI below 40 without obesity-related comorbidity.

show abstract

The Effect of the Intra-gastric Balloon on Gastric Emptying and the DeMeester Score

Cited by 18 publications

References 22 publications

The Effect of Endoscopic Bariatric and Metabolic Therapies on Gastroesophageal Reflux Disease

The Effect of Endoscopic Bariatric and Metabolic Therapies on Gastroesophageal Reflux Disease

Advanced endoscopic gastrointestinal techniques for the bariatric patient: implications for the anesthesia provider

İntragastrik Balon ve Botulinum Toksin Enjeksiyonunun Kilo Kaybı Üzerine Kısa Dönem Etkilerinin Karşılaştırılması

Contact Info

Product

Resources

About